Drug Profile
IMGN 289
Alternative Names: IMGN-289; R= J-2898-ALatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Alkylating agents; DNA cross linking agents; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 24 Apr 2015 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
- 01 Apr 2015 ImmunoGen terminates a phase I trial in Solid tumours (Late-stage disease; Second-line therapy or greater) in USA (IV) (NCT01963715)